Antibody Collaboration and Licensing Deals 2019-2026

Antibody Collaboration and Licensing Deals

The Antibody Collaboration and Licensing Deals report delivers a comprehensive and commercially focused analysis of global dealmaking across antibody therapeutics - equipping business development teams with the critical intelligence required to compete effectively in one of the most active and high-value areas of biopharma partnering.

Covering deals announced since 2019, the report provides a detailed and structured database of antibody transactions spanning collaborations, licensing agreements, and strategic partnerships across discovery, development, and commercialization.

Report Scope

This report provides a complete and actionable view of the antibody partnering landscape, combining granular deal data with contract-level insight to support confident, evidence-based decision-making.

Coverage includes:

• Collaboration and licensing deals across antibody therapeutics
• Detailed financial terms including upfronts, milestones, and royalties
• Access to underlying contract documents where disclosed
• Analysis of deal structures across antibody formats, including monoclonal antibodies, bispecifics, and antibody-drug conjugates (ADCs)
• Key Features
• Comprehensive analysis of antibody dealmaking activity and trends since 2019
• Identification of the most active and strategically relevant dealmakers
• Robust benchmarking of financial terms across comparable transactions
• Detailed evaluation of deal structures, including rights allocation and development responsibilities
• Contract-level insights into key clauses where disclosures are available
• Focused analysis of ADCs as a rapidly expanding, high-value partnering segment driving deal activity
• What This Report Enables You To Do
• Benchmark antibody and ADC deal terms with confidence
• Identify and prioritise high-value partnering opportunities
• Understand how leading companies are structuring competitive deals
• Validate deal assumptions using real-world transaction data
• Strengthen negotiation positioning with evidence-backed insights
• Save hundreds of hours of research time by accessing a fully curated, structured deal and contract dataset in one place
• Accelerate BD decision-making in a fast-moving and competitive market
• Report Structure

The report is organized into the following sections:

• Overview of antibody dealmaking
• Trends in antibody partnering activity
• Analysis of leading deals by value
• Most active companies in antibody dealmaking
• Contract analysis and deal structure insights
• Deal analysis by antibody technology type, including ADCs
• Commercial Relevance
• Antibody therapeutics remain a core pillar of biopharma dealmaking, with sustained activity across established modalities and accelerating momentum in next-generation formats.
• In particular, antibody-drug conjugates (ADCs) have emerged as one of the most competitive and capital-intensive areas of partnering, driving a surge in high-value transactions and strategic collaborations.
• In this environment, access to high-quality, deal-level and contract-level intelligence is essential.
• This report provides the insight required to benchmark effectively, identify the right partners, and execute deals with greater confidence-ensuring your BD strategy is grounded in how transactions are actually being structured and negotiated in the market today.